Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) FCF Margin: 2014-2025

Historic FCF Margin for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Sep 2025 value amounting to -120.08%.

  • Viridian Therapeutics, Inc.\DE's FCF Margin rose 7894853.00% to -120.08% in Q3 2025 from the same period last year, while for Sep 2025 it was -461.00%, marking a year-over-year increase of 6491383.00%. This contributed to the annual value of -77,096.03% for FY2024, which is 1815717.00% down from last year.
  • Viridian Therapeutics, Inc.\DE's FCF Margin amounted to -120.08% in Q3 2025, which was up 99.88% from -100,553.33% recorded in Q2 2025.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's FCF Margin ranged from a high of -120.08% in Q3 2025 and a low of -128,804.17% during Q1 2025.
  • In the last 3 years, Viridian Therapeutics, Inc.\DE's FCF Margin had a median value of -63,528.57% in 2023 and averaged -70,143.29%.
  • Over the last 5 years, Viridian Therapeutics, Inc.\DE's FCF Margin had its largest YoY gain of 7,894,853bps in 2025, and its largest YoY loss of 6,599,444bps in 2025.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's FCF Margin (Quarterly) stood at -7,765.89% in 2021, then tumbled by 2,487,506bps to -32,640.95% in 2022, then crashed by 2,020,349bps to -52,844.44% in 2023, then tumbled by 4,916,389bps to -102,008.33% in 2024, then soared by 7,894,853bps to -120.08% in 2025.
  • Its FCF Margin stands at -120.08% for Q3 2025, versus -100,553.33% for Q2 2025 and -128,804.17% for Q1 2025.